# Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)

> **NCT01508156** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 130 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** IDX719
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01508156
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2015-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508156, "Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01508156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*